Skip to main content
ROIV logo

ROIV · Roivant Sciences Ltd.

Track ROIV — free
Market Cap
$24.93B
Shares
722.32M

ROIV metrics

64 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$34.41
Market cap
$24.93B

Price action

19 metrics
Price change (1W)
-7.0%
Price change (30D)
-1.2%
Price change (3M)
+19.1%
Price change (6M)
+15.8%
Price change (YTD)
+57.5%
Price change (1Y)
+175.9%
Trailing year
Price change (5Y)
+243.5%
52-week high
$37.58
52-week low
$12.39
Change from 52-week high
-9.0%
Change from 52-week low
+175.9%
Annualized volatility
43.1%
Beta
1.1
RSI (14D)
41.4
Price vs SMA 50
-3.0%
Price vs SMA 200
+20.6%
Avg volume (3M)
6.16M
Relative volume
1.0
Average dollar volume
$210.79M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
722.32M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
3,310.5×
reciprocal yield 0.0%
P / book
5.9
reciprocal yield 17.0%
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
50.3×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
50.3×
reciprocal yield 2.0%
EV / EBIT historical average (3Y)
0.6×
reciprocal yield 172.4%
EV / EBIT historical average (5Y)
0.6×
reciprocal yield 172.4%
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
Operating margin
-7,914.8%
Trailing 12 months
Net margin
-2,837.7%
Gross profit (TTM)
Operating profit (TTM)
−$596.14M
Net income (TTM)
−$213.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.47
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$6.28

Growth

11 metrics
Revenue growth YoY
-33.5%
Year over year
Net income growth YoY
Revenue (TTM)
$7.53M
Trailing 12 months
EPS growth YoY
Shares change YoY
+6.0%
Year over year · more shares
Revenue CAGR (3Y)
-36.0%
Revenue CAGR (5Y)
-19.1%
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-5.1%
Return on assets
-4.0%
Debt / equity
Current ratio
16.7
EBITDA (TTM)
−$593.29M
Free cash flow (TTM)
Quick ratio
Interest coverage
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Cash & equivalents
$1.25B
Total assets
$5.31B
Total debt
$323.72M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$816.47M
Capital expenditures (TTM)
R&D (TTM)
$730.91M
SG&A (TTM)
$679.77M
Stock compensation (TTM)
$347.33M
R&D / revenue
9,704.0%
Stock compensation / revenue
4,611.4%

Ownership (13F)

3 metrics
13F filers
498
13F filer change QoQ
+50
Institutional ownership
79.7%

Short interest

3 metrics
Short interest
4.2%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$247.51M
Insider-sentiment score
6 / 100

Risk flags

1 metrics
Going concern
Key facts CIK 1635088 CUSIP G76279101 13F (30d) 345 filings 339 filers Visit website Investor relations